We are live on ! Find out more
AKBA icon

Akebia Therapeutics

119 hedge funds and large institutions have $593M invested in Akebia Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 16 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

891% more call options, than puts

Call options by funds: $2.2M | Put options by funds: $222K

250% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 16

51% more capital invested

Capital invested by funds: $392M → $593M (+$202M)

9% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 22

1% more funds holding

Funds holding: 118119 (+1)

0.19% less ownership

Funds ownership: 64.17%63.98% (-0.19%)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
119
Holders Change
+1
Holders Change %
+0.85%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
24
Increased
56
Reduced
16
Closed
22
Calls
$2.2M
Puts
$222K
Net Calls
+$1.98M
Net Calls Change
+$848K
Name Holding Trade Value Shares
Change
Change in
Stake
EI
26
EAM Investors
California
$4.63M +$190K +12,330 +6%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$4.41M +$372K +24,167 +12%
American Century Companies
28
American Century Companies
Missouri
$4.24M +$1.89M +122,924 +133%
Deutsche Bank
29
Deutsche Bank
Germany
$4.16M -$980K -63,751 -23%
OAM
30
Oxford Asset Management
United Kingdom
$4M +$2.08M +135,460 +196%
Ameriprise
31
Ameriprise
Minnesota
$3.08M +$1.1M +71,845 +85%
Two Sigma Investments
32
Two Sigma Investments
New York
$3.04M +$1.77M +115,208 +295%
3C
33
361 Capital
Colorado
$2.74M +$2.14M +139,489 New
DCM
34
DAFNA Capital Management
California
$2.67M
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$2.5M +$35K +2,274 +2%
Arrowstreet Capital
36
Arrowstreet Capital
Massachusetts
$2.38M +$1.26M +82,189 +211%
MOACM
37
Mutual of America Capital Management
New York
$2.19M +$1.71M +111,400 New
PPA
38
Parametric Portfolio Associates
Washington
$2.07M +$478K +31,074 +42%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$1.97M +$1.22M +79,459 +388%
Marshall Wace
40
Marshall Wace
United Kingdom
$1.8M -$114K -7,447 -8%
Wells Fargo
41
Wells Fargo
California
$1.75M +$16.5K +1,072 +1%
BIM
42
Bogle Investment Management
Massachusetts
$1.67M +$1.31M +85,131 New
Two Sigma Advisers
43
Two Sigma Advisers
New York
$1.54M +$803K +52,200 +198%
Russell Investments Group
44
Russell Investments Group
United Kingdom
$1.53M +$116K +7,571 +11%
UBS Group
45
UBS Group
Switzerland
$1.5M -$536K -34,894 -31%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$1.41M +$96K +6,244 +10%
TA
47
Teachers Advisors
New York
$1.38M +$30.1K +1,957 +3%
JIC
48
Johnson Investment Counsel
Ohio
$1.23M -$13.2K -859 -1%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.16M
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$1.08M +$840K +54,661 +24,512%

AKBA Hedge Fund Activity: Q3 2017 in Review

119 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2017, worth a combined $593M — up 51% from $392M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AKBA positions and 22 closed out — a net gain of 2 holders — while 56 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $12M sold.

  • 119 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2017, up from 118 in Q2 2017.
  • Funds reported $593M of Akebia Therapeutics stock for Q3 2017, up 51% quarter-over-quarter.
  • 24 funds opened new Akebia Therapeutics positions in Q3 2017 and 22 closed out, a net change of +2 holders.
  • The largest Akebia Therapeutics buyer in Q3 2017 was BlackRock, an estimated $15.5M added.
  • The largest Akebia Therapeutics seller in Q3 2017 was RA Capital Management, an estimated $12M sold.

Based on aggregated 13F filings for Q3 2017.